Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study

Conclusions A three-day course of oral celecoxib reduces early pain and co-analgesic consumption; however, an increase in dose, dose frequency, and duration of dose may be required for sustained pain relief in the pediatric setting. The CYP2C9*3 allele may influence recovery. This trial was registered at: ClinicalTrials.gov: NCT00849966.
Source: Canadian Journal of Anesthesia - Category: Anesthesiology Source Type: research